EP0805680A2 - Combinational drugs for treating migraine and other illnesses, comprising sesquiterpene lactones and b-complex vitamins - Google Patents

Combinational drugs for treating migraine and other illnesses, comprising sesquiterpene lactones and b-complex vitamins

Info

Publication number
EP0805680A2
EP0805680A2 EP96900799A EP96900799A EP0805680A2 EP 0805680 A2 EP0805680 A2 EP 0805680A2 EP 96900799 A EP96900799 A EP 96900799A EP 96900799 A EP96900799 A EP 96900799A EP 0805680 A2 EP0805680 A2 EP 0805680A2
Authority
EP
European Patent Office
Prior art keywords
composition
sesquiterpene lactone
riboflavin
complex vitamin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96900799A
Other languages
German (de)
French (fr)
Inventor
Natalie J. Lazarowych
Peter Pekos
Michael O'connell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ashbury Research Corp
Original Assignee
Ashbury Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ashbury Research Corp filed Critical Ashbury Research Corp
Publication of EP0805680A2 publication Critical patent/EP0805680A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to compositions and methods useful in the treatment of migraine headaches and related illnesses.
  • migraine migraine including cluster headaches
  • Treatment for many patients having the occasional migraine involves simple analgesics with or without sedatives. Approximately 10% of migraine sufferers have three or more attacks per month and warrant prophylactic treatment. Twenty-five to fifty percent of this group benefit from treatment with beta-adrenoreceptor blocking agents, clonidine or, in the female sufferer, gestagen hormones.
  • beta-adrenoreceptor blocking agents clonidine
  • Feverfew rich in sesquiterpene lactones, principally parthenolide
  • sixty-eight percent of migraine sufferers displayed improvement when treated prophylactically with riboflavin.
  • Non-selective antagonist drugs will, therefore, not only reduce the smooth muscular spasm (of intracranial blood vessels in the case of migraine, or bronchial smooth muscle in the case of asthma) but also the pain
  • Sesquiterpene lactones are known to be present in many plants, for example in Asteracea, Magnoliaceae, and in particular in Tanacetum parthenium
  • a sesquiterpene lactone or a source of sesquiterpene lactones, such as sesquiterpene lactone-containing plants and plant extracts, is used in combination with a B-complex vitamin, such as riboflavin.
  • Preparations comprising such a combination are also provided that have pharmaceutical use, particularly in the treatment of migraine, including cluster, headaches and various arthritic and bronchial conditions, such as asthma.
  • the B-complex vitamin that is useful in accordance with the present invention includes riboflavin, riboflavin phosphate, flavin adenine dinucleotide, nicotinic acid, folic acid, cyanocobalmin, para-amino benzoic acid, thiamine, py ⁇ ' doxine, pantothenic acid, biotin, choline inositol, and carnitine.
  • the sesquiterpene lactone that is useful in accordance with the present invention includes germacranolides, guaianolides, and pseudoguaianolides, in particular those sesquiterpene lactones having an ⁇ -methylene substituent in the lactone ring, such as parthenolide.
  • Parthenolide and sesquiterpene lactone- containing plant materials, such as feverfew leaf or extracts from such plant materials are preferred.
  • These natural-sources of actives are preferred because they deliver many active components, not only a single chemical entity.
  • the variety of active components and active chemical species present results in preparations with a broader spectrum of activity compared to pure sesquterpine lactones.
  • both sesquiterpene lactones and B-complex vitamins have been found, individually, to be effective for treatment or prophylaxis of migraine
  • the combination of the two types of actives leads to synergistic effects.
  • a combination of feverfew or other source of parthenolide with a B-vitamin additive leads to a further decrease in the frequency of the attacks and causes the attacks to be less painful.
  • An increased percentage of migraine sufferers should therefore display an improvement in frequency, severity, or both, when treated prophylactically with the combinational drug.
  • the combinational drug has low toxicity, surprisingly few side-effects and may be taken for the extended periods required for effective prophylaxis, without adverse reactions.
  • the dosage of active ingredients will, of course, vary from individual to individual and will depend upon many factors, including body weight, metabolism, and the like. In general, however, it is believed that, in both treatment and prophylaxis, a given individual should receive from about 50 to about 10,000 micrograms, preferably from about 250 to about 1000 micrograms, and most preferably about 250 micrograms of sesquiterpene lactone, such as parthenolide, per day. In general, it is also believed that a given individual should receive from about 0.1 to about 5,000 milligrams, preferably from about 100 to about 500 milligrams, and most preferably about 400 milligrams of B- complex vitamin, especially riboflavin, per day. More, however, may be need in the case of acute attacks.
  • pharmaceutical dosage forms contain from about 50 to about 10,000 micrograms, preferably from about 250 to about 1000 micrograms, and most preferably about 250 micrograms of sesquiterpene lactone, such as parthenolide, in combination with about 0.1 to about 5,000 milligrams, preferably from about 100 to about 500 milligrams, and most preferably about 400 milligrams of B-complex vitamin, especially riboflavin, per day.
  • such pharmaceutical dosage forms may comprise from about 5 to 300 mg, especially 50 to 200 mg, of feverfew leaf, containing about 250 micrograms of parthenolide, in combination with from about 0.1 to 400 mg of riboflavin per day.
  • the feverfew dosage may be adjusted to accommodate the naturally variable levels of sesquiterpene lactones, such as parthenolide.
  • a particularly preferred capsule contains about 125 mg of high-parthenolide feverfew and 400 mg of riboflavin.
  • composition of the present invention be administered as two tablets daily; each tablet containing 125 mg feverfew (containing 250 mg of sesquiterpene lactone) and 200 mg riboflavin or other B-complex vitamin.
  • the combination of actives may also be administered by independent dosage forms. For example, two tablets of feverfew, each containing 250 ⁇ grams of parthenolide may be taken daily in addition to two tablets of B complex vitamin, each containing 200 mgrams of riboflavin.
  • the preparations may be administered orally, or parenterally and conveniently take the form of a tablet, caplet, capsule, lozenge, injectable solution, liquid suspension or elixir. Circumstances may arise wherein the dose is best administered by suppository, inhalation, slow release implant, slow release patch or other topical vehicle.
  • the combination of active ingredients are usually best given in an oral form made up as a tablet, caplet, capsule, or as a liquid suspension or elixir one or two times daily.
  • oral administration the preparation may be admixed with any conventional tableting or capsuling carrier, or as a suspension or solution in any orally acceptable non-toxic liquid carrier.
  • the drug may be provided in encapsulated form for sustained release over a period of time.
  • parenteral administration the drug may be provided as a suspension or solution in any suitable, sterile injection medium, e.g. sterile aqueous saline solution
  • the pharmaceutical formulations may additionally include, in addition to the aforementioned active agents, other known anti-migraine preparations, sedatives and relaxants, analgesics and antiemetics such as:
  • Excellent efficacy of a preparation in accordance with this invention is likely in all forms of migraine including the treatment of classical and common migraine, migrainous neuralgia (cluster headache), and premenstrual and menstrual migraine and other headaches.
  • compositions of the present invention may be used in the prevention of the aforementioned types of headache by reducing the frequency, severity and duration of the attacks and by reducing the nausea and vomiting symptoms.
  • the compositions may also be used to treat acute attacks of the aforementioned types of headache, by reducing their duration, severity and the intensity of associated symptoms.
  • preparations in accordance with the invention may be administered orally, or parenterally and conveniently take the form of a tablet, capsule, injectable, liquid suspension or elixir. Circumstances may arise where it is best administered by suppository, inhalation, slow release implant, slow release patch, or other topical vehicle. Dosage and administration are as indicated above.
  • a preparation in accordance with the invention may additionally include other anti-arthritis agents including non-steroidal anti-inflammatory drugs, analgesics, skeletal muscle relaxants, steroids, gold and penicillamine.
  • agents examples include aspirin, indomethacin, piroxicam, benorylate, ibuprofen, paracetamol, salicylamine, diflunizal, ethoheptazine, fenoprofen (calcium fenoprofate) flufenamic acid, mefenamic acid, naproxen sodium, ketoprofen, phenylbutazone, sulindac, penicillamine, salicylate, fenclofenac, flurbiprofen, fenbufen, feprazone, sodium aurothiomalate, naproxen, benoxaprofen, aloxipria, hydroxychloroquine sulphate, azapropazone, tolemtin, choline magnesium trisalicylate, diclofenac, adrenal steroids such as prednisone or prednisolone, white willowbark and its extracts, other non-steroidal anti-inflammatory agents of
  • compositions of the present invention may be used in the treatment of rheumatoid arthritis, osteoarthritis, arthritis associated with Felty's syndrome,
  • Still's disease systemic lupus erythematosus, polyarteritis nodosa, scleroderma, gout, achalasia of the cardia, Crohn's disease, chronic brucellosis, ankylosing spondylitis, sarcoidosis, psoriasis and gonorrhoea.
  • the preparations are believed to be useful in the prevention of the above arthritides, being effective in reducing the frequency, severity and duration of the symptoms.
  • the preparations can also be used to treat the acute attacks of the above arthritides reducing their duration, severity and associated symptoms.
  • compositions of the present invention can be enhanced by the presence of gamma linoleic acid.
  • the compositions may comprise, in addition to a sesquiterpene lactone and a B- complex vitamin, gamma linoleic acid or a source thereof.
  • the linoleic acid source may be, for example, evening primrose oil or borage oil.
  • preparations in accordance with the invention may be administered orally, or parenterally and conveniently take the form of a tablet, capsule, injectable, liquid suspension or elixir. Circumstances may arise where it is best administered by suppository, inhalation, slow release implant, slow release patch or other topical vehicle. Dosage and administration are as indicated above.
  • a preparation in accordance with the invention may be co-administered with or additionally include other ingredients such as bronchodilator, antihistamine and anti-infective agents, examples of which agents are: isoprenaline sulphate, orciprenaline, adrenaline, terbutaline sulphate, theophylline, brazilian cocoa choline theophyllinate, aminophylline, ephedrine hydrochloride, papaverine hydrochloride, ipratropium bromide, atropine methonitrate, beclomethasone dipropionate, fenoterol hydrobromide, betamethasone, isoetharine mesylate or hydrochloride, phenylephrine hydrochloride or bitartrate, thenyldiamine hydrochloride, reproterol hydrochloride, deptropine citrate, butethamate citrate, acepifylline, diphenylpyraline hydrochloride, sodium
  • H1 -receptor antagonists diprophylline, methoxyphenamine hydrochloride, rimiterol hydrobromide, hyoscine hydrobromide, salbutamol sulphate, ketotifen hydrogen fumarate, pseudo-ephedrine hydrochloride, bromhexine hydrochloride, and antifungal, antibacterial and antiviral agents.
  • the composition in accordance with the present invention is believed to be useful in the treatment of bronchial asthma, bronchoconstriction associated with chronic bronchitis, and symptoms associated with histamine release in allergic hypersensitivity phenomena such as hay fever and anaphylaxis.
  • Compositions in accordance with the invention will now be illustrated in more detail with reference to the following Examples:
  • Powdered feverfew leaf and riboflavin are mixed in the following proportions:
  • the mixture is encapsulated into a soft shell capsule or hard shell capsule or two piece hard shell gelatin capsules.
  • the capsules may be treated to retard disintegration or absorption by the use of gastro-resistant coatings, such as hydroxymethyl propyl cellulose, or the content may be mixed with polymeric matrix materials as those known to the pharmaceutical industry, to release the active ingredients at a controlled rate.
  • gastro-resistant coatings such as hydroxymethyl propyl cellulose
  • the soft shell or two piece hard shell gelatin capsule may be used via the oral or rectal route.
  • the pH is adjusted to between 2 and 6.5, using HCI.
  • the injectable may be administered by intramuscular, subcutaneous, or intravenous injection.
  • the preparation should be stored in tight, light-resistant containers, preferably between 15-25° C.
  • Caplets may be enteric coated, sugar coated, film coated or prepared as a laminated tablet.
  • the dry solids are triturated and the purified water is slowly added with trituration.
  • the pH is adjusted to between 3 and 6.5 using HCI as required.
  • the suspension may be administered by ingestion.
  • the preparation should be stored in tight, light-resistant containers, preferably between 15-25°C.

Abstract

A preparation for pharmaceutical use, especially in the treatment of migraine, cluster headaches, arthritis and bronchial complaints, comprises a sesquiterpene lactone such as parthenolide and B-complex vitamins such as riboflavin (vitamin B2), as well as a method of treating and providing prophylaxis against such illnesses by use of such a combination.

Description

COMBINAΗONAL DRUGS FOR TREATING MIGRAINE AND OTHER ILLNESSES. COMPRISING SESQUΠΈRPENE LACTONES AND B-COMPLEX VΓTAMINS
FIELD OF THE INVENTION This invention relates to compositions and methods useful in the treatment of migraine headaches and related illnesses.
BACKGROUND OF THE INVENTION
The incidence of migraine including cluster headaches, is said to be approximately 10-20% of the male population and 20-30% of the female population. Treatment for many patients having the occasional migraine involves simple analgesics with or without sedatives. Approximately 10% of migraine sufferers have three or more attacks per month and warrant prophylactic treatment. Twenty-five to fifty percent of this group benefit from treatment with beta-adrenoreceptor blocking agents, clonidine or, in the female sufferer, gestagen hormones. In the remaining population of migraine sufferers, and in those with intolerable side-effects from available drugs, there is a lack of conventional pharmaceutical preparations that exhibit therapeutic effect, without severe side-effects. Feverfew, rich in sesquiterpene lactones, principally parthenolide, has also been shown to have a prophylactic effect against migraine. In one study, more than 70% of the feverfew users claimed that the herb had decreased the frequency of their attacks, caused them to be less painful, or both. In another study, sixty-eight percent of migraine sufferers displayed improvement when treated prophylactically with riboflavin.
Although the precise cause or causes of migraine, arthritis, and asthma remain unknown, all three diseases are associated with a postulated local or systemic release of active substances including, in the case of migraine and/or its variants: norepinephhne (noradrenaline), 5-hydroxytryptamine (serotonin), histamine, prostaglandins and bradykinin; in the case of arthritis; prostaglandins, histamine, 5-hydroxytryptamine and bradykinin; and in the case of asthma; histamine, 5-hydroxytryptamine, bradykinin, acetylcholine, prostaglandins and the leukotrienes. These endogenous substances have in common the ability to cause smooth muscle to contract (i.e. go into spasm), and many are also pain- producing substances, e.g. 5-hydroxytryptamine, bradykinin, histamine and prostaglandins. Non-selective antagonist drugs will, therefore, not only reduce the smooth muscular spasm (of intracranial blood vessels in the case of migraine, or bronchial smooth muscle in the case of asthma) but also the pain
(of migraine and arthritis) associated with their release. Sesquiterpene lactones are known to be present in many plants, for example in Asteracea, Magnoliaceae, and in particular in Tanacetum parthenium
(feverfew), and are thought to be responsible for observed bioactivity of the leaf material.
SUMMARY OF THE INVENTION
It has now been discovered that a mixture of a sesquiterpene lactone and a B-vitamin, is especially effective in both the treatment and prophylaxis of migraine, arthritis, and asthma.
In accordance with the present invention, a sesquiterpene lactone, or a source of sesquiterpene lactones, such as sesquiterpene lactone-containing plants and plant extracts, is used in combination with a B-complex vitamin, such as riboflavin. Preparations comprising such a combination are also provided that have pharmaceutical use, particularly in the treatment of migraine, including cluster, headaches and various arthritic and bronchial conditions, such as asthma.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The B-complex vitamin that is useful in accordance with the present invention includes riboflavin, riboflavin phosphate, flavin adenine dinucleotide, nicotinic acid, folic acid, cyanocobalmin, para-amino benzoic acid, thiamine, pyπ'doxine, pantothenic acid, biotin, choline inositol, and carnitine.
The sesquiterpene lactone that is useful in accordance with the present invention includes germacranolides, guaianolides, and pseudoguaianolides, in particular those sesquiterpene lactones having an α-methylene substituent in the lactone ring, such as parthenolide. Parthenolide and sesquiterpene lactone- containing plant materials, such as feverfew leaf or extracts from such plant materials are preferred. These natural-sources of actives are preferred because they deliver many active components, not only a single chemical entity. The variety of active components and active chemical species present results in preparations with a broader spectrum of activity compared to pure sesquterpine lactones.
Although both sesquiterpene lactones and B-complex vitamins have been found, individually, to be effective for treatment or prophylaxis of migraine, the combination of the two types of actives, in accordance with the present invention, leads to synergistic effects. Thus, a combination of feverfew or other source of parthenolide with a B-vitamin additive leads to a further decrease in the frequency of the attacks and causes the attacks to be less painful. An increased percentage of migraine sufferers should therefore display an improvement in frequency, severity, or both, when treated prophylactically with the combinational drug. The combinational drug has low toxicity, surprisingly few side-effects and may be taken for the extended periods required for effective prophylaxis, without adverse reactions.
Dosage And Pharmaceutical Preparation The dosage of active ingredients will, of course, vary from individual to individual and will depend upon many factors, including body weight, metabolism, and the like. In general, however, it is believed that, in both treatment and prophylaxis, a given individual should receive from about 50 to about 10,000 micrograms, preferably from about 250 to about 1000 micrograms, and most preferably about 250 micrograms of sesquiterpene lactone, such as parthenolide, per day. In general, it is also believed that a given individual should receive from about 0.1 to about 5,000 milligrams, preferably from about 100 to about 500 milligrams, and most preferably about 400 milligrams of B- complex vitamin, especially riboflavin, per day. More, however, may be need in the case of acute attacks.
Thus, in accordance with the present invention, pharmaceutical dosage forms are provided that contain from about 50 to about 10,000 micrograms, preferably from about 250 to about 1000 micrograms, and most preferably about 250 micrograms of sesquiterpene lactone, such as parthenolide, in combination with about 0.1 to about 5,000 milligrams, preferably from about 100 to about 500 milligrams, and most preferably about 400 milligrams of B-complex vitamin, especially riboflavin, per day.
In general, such pharmaceutical dosage forms may comprise from about 5 to 300 mg, especially 50 to 200 mg, of feverfew leaf, containing about 250 micrograms of parthenolide, in combination with from about 0.1 to 400 mg of riboflavin per day. For treatment, more than one dose may be required, as in the case of the treatment of an acute attack of migraine or allied disorder. The feverfew dosage may be adjusted to accommodate the naturally variable levels of sesquiterpene lactones, such as parthenolide. A particularly preferred capsule contains about 125 mg of high-parthenolide feverfew and 400 mg of riboflavin.
It is preferred that the composition of the present invention be administered as two tablets daily; each tablet containing 125 mg feverfew (containing 250 mg of sesquiterpene lactone) and 200 mg riboflavin or other B-complex vitamin. The combination of actives may also be administered by independent dosage forms. For example, two tablets of feverfew, each containing 250 μgrams of parthenolide may be taken daily in addition to two tablets of B complex vitamin, each containing 200 mgrams of riboflavin.
For the treatment or prophylaxis of migraine the preparations may be administered orally, or parenterally and conveniently take the form of a tablet, caplet, capsule, lozenge, injectable solution, liquid suspension or elixir. Circumstances may arise wherein the dose is best administered by suppository, inhalation, slow release implant, slow release patch or other topical vehicle.
The combination of active ingredients are usually best given in an oral form made up as a tablet, caplet, capsule, or as a liquid suspension or elixir one or two times daily. For oral administration, the preparation may be admixed with any conventional tableting or capsuling carrier, or as a suspension or solution in any orally acceptable non-toxic liquid carrier. If desired, the drug may be provided in encapsulated form for sustained release over a period of time. For parenteral administration the drug may be provided as a suspension or solution in any suitable, sterile injection medium, e.g. sterile aqueous saline solution
Given the desired dosage rates indicated above, the appropriate method of formulation of the drug in a form suitable for oral or parenteral administration will be obvious to persons skilled in the art. The same applies for inhalants and rectal or slow-release implant modes of administration, which are also feasible. The pharmaceutical formulations may additionally include, in addition to the aforementioned active agents, other known anti-migraine preparations, sedatives and relaxants, analgesics and antiemetics such as:
Propranolol Hydrochloride Ergotamine tartrate
Methysergide Maleate
Dihydroergotamine Mesylate
Clonidine Hydrochloride
Isometheptene Mucate Buclizine Dihydrochloride
Metoclopramide Hydrochloride
Pizotifen Hydrogen Malate
Aspirin and other non-steroidal anti-inflammatory agents
White willow bark and its extracts Other non-steroidal anti-inflammatory agents of plant origin Paracetamol and other minor analgesics
Pentazocine Hydrochloride
Prochlorperazine
Caffeine Meprobamate
Ethoheptazine Citrate
Zomepirac
Meptazinol Hydrochloride
DEH Sumatriptin
Ginger
Brazilian Cocoa
Capsaicin
Magnesium Melatonin
Vitamin D
Calcium
Chamomile
Milk Thistle Valerian
Peppermint
Eucalyptus
Excellent efficacy of a preparation in accordance with this invention is likely in all forms of migraine including the treatment of classical and common migraine, migrainous neuralgia (cluster headache), and premenstrual and menstrual migraine and other headaches.
The compositions of the present invention may be used in the prevention of the aforementioned types of headache by reducing the frequency, severity and duration of the attacks and by reducing the nausea and vomiting symptoms. The compositions may also be used to treat acute attacks of the aforementioned types of headache, by reducing their duration, severity and the intensity of associated symptoms.
For the treatment of arthritic conditions, preparations in accordance with the invention may be administered orally, or parenterally and conveniently take the form of a tablet, capsule, injectable, liquid suspension or elixir. Circumstances may arise where it is best administered by suppository, inhalation, slow release implant, slow release patch, or other topical vehicle. Dosage and administration are as indicated above. A preparation in accordance with the invention may additionally include other anti-arthritis agents including non-steroidal anti-inflammatory drugs, analgesics, skeletal muscle relaxants, steroids, gold and penicillamine.
Examples of such agents are: aspirin, indomethacin, piroxicam, benorylate, ibuprofen, paracetamol, salicylamine, diflunizal, ethoheptazine, fenoprofen (calcium fenoprofate) flufenamic acid, mefenamic acid, naproxen sodium, ketoprofen, phenylbutazone, sulindac, penicillamine, salicylate, fenclofenac, flurbiprofen, fenbufen, feprazone, sodium aurothiomalate, naproxen, benoxaprofen, aloxipria, hydroxychloroquine sulphate, azapropazone, tolemtin, choline magnesium trisalicylate, diclofenac, adrenal steroids such as prednisone or prednisolone, white willowbark and its extracts, other non-steroidal anti-inflammatory agents of plant origin evening primrose oil gamma linoleic acid borage oil flax seed
The compositions of the present invention may be used in the treatment of rheumatoid arthritis, osteoarthritis, arthritis associated with Felty's syndrome,
Still's disease, systemic lupus erythematosus, polyarteritis nodosa, scleroderma, gout, achalasia of the cardia, Crohn's disease, chronic brucellosis, ankylosing spondylitis, sarcoidosis, psoriasis and gonorrhoea.
The preparations are believed to be useful in the prevention of the above arthritides, being effective in reducing the frequency, severity and duration of the symptoms. The preparations can also be used to treat the acute attacks of the above arthritides reducing their duration, severity and associated symptoms.
It is also believed that the efficacy of the compositions of the present invention can be enhanced by the presence of gamma linoleic acid. Thus, the compositions may comprise, in addition to a sesquiterpene lactone and a B- complex vitamin, gamma linoleic acid or a source thereof. The linoleic acid source may be, for example, evening primrose oil or borage oil.
For the treatment of asthma, preparations in accordance with the invention may be administered orally, or parenterally and conveniently take the form of a tablet, capsule, injectable, liquid suspension or elixir. Circumstances may arise where it is best administered by suppository, inhalation, slow release implant, slow release patch or other topical vehicle. Dosage and administration are as indicated above.
A preparation in accordance with the invention may be co-administered with or additionally include other ingredients such as bronchodilator, antihistamine and anti-infective agents, examples of which agents are: isoprenaline sulphate, orciprenaline, adrenaline, terbutaline sulphate, theophylline, brazilian cocoa choline theophyllinate, aminophylline, ephedrine hydrochloride, papaverine hydrochloride, ipratropium bromide, atropine methonitrate, beclomethasone dipropionate, fenoterol hydrobromide, betamethasone, isoetharine mesylate or hydrochloride, phenylephrine hydrochloride or bitartrate, thenyldiamine hydrochloride, reproterol hydrochloride, deptropine citrate, butethamate citrate, acepifylline, diphenylpyraline hydrochloride, sodium cromoglycate, etamiphylline camsylate, theophylline monoethanolamine, etafedrine hydrochloride, bufylline, guaiphencain, diphenydramine hydrochloride and other histamine,
H1 -receptor antagonists, diprophylline, methoxyphenamine hydrochloride, rimiterol hydrobromide, hyoscine hydrobromide, salbutamol sulphate, ketotifen hydrogen fumarate, pseudo-ephedrine hydrochloride, bromhexine hydrochloride, and antifungal, antibacterial and antiviral agents. The composition in accordance with the present invention is believed to be useful in the treatment of bronchial asthma, bronchoconstriction associated with chronic bronchitis, and symptoms associated with histamine release in allergic hypersensitivity phenomena such as hay fever and anaphylaxis. Compositions in accordance with the invention will now be illustrated in more detail with reference to the following Examples:
EXAMPLE 1 Preparation of Capsules:
Powdered feverfew leaf and riboflavin are mixed in the following proportions:
standardized feverfew leaf powder
(containing at least 0.2% parthenolide) 125 mg riboflavin 400 mg
The mixture is encapsulated into a soft shell capsule or hard shell capsule or two piece hard shell gelatin capsules. The capsules may be treated to retard disintegration or absorption by the use of gastro-resistant coatings, such as hydroxymethyl propyl cellulose, or the content may be mixed with polymeric matrix materials as those known to the pharmaceutical industry, to release the active ingredients at a controlled rate. The soft shell or two piece hard shell gelatin capsule may be used via the oral or rectal route.
EXAMPLE 2 Preparation of tablets:
The following ingredients are mixed in the given relative proportions:
standardized feverfew leaf powder
(rich in sesquiterpene lactones) 60 mg riboflavin 200 mg milk sugar (powder) 150 mg starch 44 mg talc 40 mg stearic acid 1.4 mg tartaric acid as required All ingredients are mixed thoroughly. Sufficient tartaric acid should be used in this mixture to adjust the pH to between 2 and 6.5, preferably to pH 4.5. The mixture is compressed into slugs, which are ground and screened to 14-16 mesh granules, which are then recompressed into tablets. The tablets may be enteric coated, sugar coated, film coated or prepared as a laminated tablet. Two tablets are recommended for daily ingestion.
EXAMPLE 3
Preparation of injectable: The following are mixed: parthenolide 2500 μg riboflavin 2 g
USP water for injection 10 ml
The pH is adjusted to between 2 and 6.5, using HCI.
The injectable may be administered by intramuscular, subcutaneous, or intravenous injection. The preparation should be stored in tight, light-resistant containers, preferably between 15-25° C.
EXAMPLE 4
Preparation of caplets:
The following ingredients are mixed in the given relative proportions: standardized feverfew leaf powder
(rich in sesquiterpene lactones) 60 g riboflavin 750 g starch 95 g lactose 42 g zein 45 g magnesium stearate 8 g The mixture of riboflavin, starch and lactose is granulated with zein (10% in ethyl alcohol, adding additional alcohol if necessary to obtain good wet granules). The granulated mixture is wet screened through 8 stainless steel screen and dry at 40 to 50°C, and is then dry screened through a #20 stainless steel screen. Feverfew leaf powder is then added, which has been screened using a #8 stainless steel screen. The composition is then mixed thoroughly, lubricated and compressed into caplets. Each caplet should weigh 500 mg.
Caplets may be enteric coated, sugar coated, film coated or prepared as a laminated tablet.
EXAMPLE 5
Preparation of suspension:
The following are mixed: methyl cellulose 0.5 g standardized feverfew leaf powder
(rich in sesquiterpene lactones) 2.0 g riboflavin 4.0 g purified water 100 ml benzoic acid (preservative) 0.1 g flavoring agent (e.g.: vanillin) 0.1 ml
The dry solids are triturated and the purified water is slowly added with trituration. The pH is adjusted to between 3 and 6.5 using HCI as required. The suspension may be administered by ingestion. The preparation should be stored in tight, light-resistant containers, preferably between 15-25°C.

Claims

What is claimed is:
1. A pharmaceutical composition useful for alleviating migraine and related headaches, arthritis and asthma comprising: A) a sesquiterpene lactone; and
B) a B-complex vitamin.
2. The composition of claim 1 wherein the sesquiterpene lactone is provided by a source selected from the group consisting of plant materials and plant extracts containing sesquiterpene lactone.
3. The composition of claim 1 wherein the sesquiterpene lactone is provided by a source selected from the group consisting of feverfew leaf powder and feverfew extract.
4. The composition of claim 1 wherein the sesquiterpene lactone is provided by a source selected from the group consisting of Asteracea leaf powder and Asteracea extract.
5. The composition of claim 1 wherein the sesquiterpene lactone is provided by a source selected from the group consisting of Magnoliacea leaf powder and Magnoliacea extract.
6. The composition of claim 1 wherein the sesquiterpene lactone is parthenolide.
7. The composition of claim 1 wherein B-complex vitamin is riboflavin.
8. The composition of claim 3 wherein the B-complex vitamin is riboflavin.
9. The pharmaceutical preparation of claim 1 which comprises feverfew leaf powder in combination with riboflavin.
10. The pharmaceutical preparation of claim 1 which comprises parthenolide in combination with riboflavin.
11. The pharmaceutical composition of claim 1 in the form of a tablet, capsule, caplet, lozenge, suspension, elixir, injectable, inhalant, suppository, slow-release implant, slow-release patch or other topical vehicle.
12. The pharmaceutical composition of claim 3 in the form of a tablet, capsule, caplet, lozenge, suspension, elixir, injectable, inhalant, suppository, slow-release implant, slow-release patch or other topical vehicle.
13. A method of treating a patient suffering from an illness selected from the group consisting of migraine, arthritis, and asthma by administering to said patient both a source of sesquiterpene lactone and a B-complex vitamin, in a therapeutically effective amount.
14. The method of claim 12 wherein the sesquiterpene lactone and the
B-complex vitamin are administered by independent dosage forms.
15. The method of claim 12 wherein the sesquiterpene lactone and the B-complex vitamin are administered in the same dosage form.
16. A method of preventing or reducing the severity of an illness selected from the group consisting of migraine, arthritis, and asthma by administering to said patient both a source of sesquiterpene lactone and a B-complex vitamin, in a prophylactically effective amount.
17. The method of claim 15 wherein the sesquiterpene lactone and the B-complex vitamin are administered by independent dosage forms.
18. The method of claim 16 wherein the sesquiterpene lactone and the B-complex vitamin are administered in the same dosage form.
19. The composition of claim 1 also comprising gamma linoleic acid.
20. The composition of claim 19 wherein gamma lineoleic acid source is selected from the group consisting of evening primrose or borage oil.
21. The composition of claim 20 wherein the source of sesquiterpene lactone is feverfew and the B-complex vitamin is riboflavin.
22. The composition of claim 1 comprising feverfew, riboflavin, and a nonsteroidal anti-inflammatory drug.
23. The composition of claim 22 wherein the nonsteroidal anti- inflammatory drug is of plant origin.
24. The composition of claim 23 wherein the nonsteroidal anti- inflammatory drug is white willow bark or its extracts.
EP96900799A 1995-01-26 1996-01-25 Combinational drugs for treating migraine and other illnesses, comprising sesquiterpene lactones and b-complex vitamins Withdrawn EP0805680A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2141126 1995-01-26
CA002141126A CA2141126A1 (en) 1995-01-26 1995-01-26 Combinational drug for treating migraine and other illnesses
PCT/CA1996/000052 WO1996022774A2 (en) 1995-01-26 1996-01-25 Combinational drugs for treating migraine and other illnesses, comprising sesquiterpene lactones and b-complex vitamins

Publications (1)

Publication Number Publication Date
EP0805680A2 true EP0805680A2 (en) 1997-11-12

Family

ID=4155120

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96900799A Withdrawn EP0805680A2 (en) 1995-01-26 1996-01-25 Combinational drugs for treating migraine and other illnesses, comprising sesquiterpene lactones and b-complex vitamins

Country Status (6)

Country Link
EP (1) EP0805680A2 (en)
JP (1) JPH10512573A (en)
KR (1) KR19980701720A (en)
AU (1) AU4478096A (en)
CA (1) CA2141126A1 (en)
WO (1) WO1996022774A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2283122A1 (en) * 1997-03-03 1998-09-11 Laboratoires Remilea Plant extract compositions, method of preparation, and pharmaceutical compositions containing them
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6068999A (en) * 1998-06-25 2000-05-30 Hendrix; Curt Dietary supplement for supporting cerebrovascular tone and treating migraine headaches
DE19844836A1 (en) * 1998-09-30 2000-04-20 Hexal Ag Pharmaceutical, effective, herbal preparation for the treatment of migraines
DK0951842T3 (en) 1999-01-20 2003-01-06 Nutricia Nv Nutritional product for an infant
US6312736B1 (en) * 1999-12-09 2001-11-06 Biotech Corporation Herbal composition to relieve pain
US6890946B2 (en) 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
EP1242071A4 (en) * 1999-12-23 2004-12-29 Advanced Res & Tech Inst Use of parthenolide to inhibit cancer
US7192614B2 (en) * 2002-11-05 2007-03-20 Gelstat Corporation Compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms
US20040247705A1 (en) * 2003-06-06 2004-12-09 Roberts Stephen C. Transdermal compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms
WO2008010335A1 (en) * 2006-07-21 2008-01-24 Mmt Co., Ltd. Plant extract having arthritis-preventive effect
WO2008075466A1 (en) * 2006-12-20 2008-06-26 Mmt Co., Ltd. Food and drink, quasi drug and pharmaceutical composition for promoting hair growth, and method for promoting hair growth
WO2008075649A1 (en) * 2006-12-20 2008-06-26 Mmt Co., Ltd. Food or drink, quasi drug and medicinal composition for promoting hair growth and method of promoting hair growth
CN101278928B (en) 2007-04-06 2011-09-07 常州高新技术产业开发区三维工业技术研究所有限公司 Medicament composition containing levocarnitine or its derivatives and use thereof
US20100284986A1 (en) * 2009-05-06 2010-11-11 Kelleher Kevin J Compositions and methods for prevention and treatment of migraines
IT201700085185A1 (en) * 2017-07-26 2019-01-26 Cristalfarma S R L Food supplement for use as an adjunct in the treatment and prophylaxis of migraine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4173M (en) * 1965-02-01 1966-05-23
CA1270843A (en) * 1982-05-19 1990-06-26 Edward Stewart Johnson Sesquiterpene lactones
US4542026A (en) * 1983-04-29 1985-09-17 Jose Rios Method of treating vasomotor disorders
JPS63303915A (en) * 1987-06-05 1988-12-12 Nikko Sogyo Kk Hair tonic
DE3808141A1 (en) * 1988-03-11 1989-09-21 Mai Jutta Composition for controlling migraine
JPH0713021B2 (en) * 1991-08-01 1995-02-15 文夫 堂園 Oral drug for treatment of digestive system diseases
JPH05306231A (en) * 1992-04-24 1993-11-19 Pola Chem Ind Inc Skin external preparation
WO1994001899A1 (en) * 1992-07-02 1994-01-20 W. L. Gore & Associates, Inc. Sealing frame and protective membrane for a radar dish or horn

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9622774A2 *

Also Published As

Publication number Publication date
WO1996022774A3 (en) 1996-09-26
AU4478096A (en) 1996-08-14
JPH10512573A (en) 1998-12-02
WO1996022774A2 (en) 1996-08-01
KR19980701720A (en) 1998-06-25
CA2141126A1 (en) 1996-07-27

Similar Documents

Publication Publication Date Title
US4758433A (en) Oil extract of Tanacetum parthenium for treating migraine
WO1996022774A2 (en) Combinational drugs for treating migraine and other illnesses, comprising sesquiterpene lactones and b-complex vitamins
TW389696B (en) Accelerated release composition containing bromocriptine
US20060204599A1 (en) Dietary supplement and method of using same
JP2002518456A (en) Dietary supplements to support normal cerebrovascular conditions
JP2008501655A (en) Meloxicam-containing composition
WO2005084392A2 (en) 4-methylpyrazole formulations for inhibiting ethanol intolerance
JP3018160B2 (en) Drug for reducing dysmenorrhea and / or premenstrual syndrome
JPS59112948A (en) Cholesterol level lowering agent
EA002166B1 (en) Pharmaceutical combinations containing tramadol - a medicament for ttreating migraine
CZ289395A3 (en) Transdermic therapeutic system for administration of serotonin agonists
US5082665A (en) Anti-snoring formulations using yohimbine
JP2001518481A (en) Serotonin-containing preparations for oral administration and methods of use
US4794112A (en) Acetaminophen/hydroxyzine analgesic combinations
US5011841A (en) Treatment of depression
US5026706A (en) Method for treating dysuria using naftopidil
Sjaastad et al. 2‐(2.6‐dichlorophenylamino)‐2‐imidazoline hydrochloride (ST 155 or Catapresan) as a prophylactic remedy against migraine
GB2248392A (en) Composition to combat alcoholism
US20110117070A1 (en) Compositions and methods for treating headache
JP2001097856A (en) Antitussive
US4515802A (en) Analgesic preparations
AU2775500A (en) Combinational drugs for treating migraine and other illnesses, comprising sesquiterpene lactones and B-complex vitamins
JPH04173741A (en) Agent for preventing and treating hypertension
GB2135884A (en) Analgesic preparations containing tizanidine and paracetamol
JPH0232020A (en) Method and drug for suppressing manifestation of tolerance in morphine analgestic treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970822

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000821

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010301